P01 AI189362-01A1 Project 2- 08/2025-06/2030 - NIH/NIAID
Translating germline-targeting HIV Env SOSIP immunization of infants: targeting bnAbs in early life
MPI: Sallie Permar, MD, PhD, Weill Cornell Medicine
The overall goal is to to develop BG505 GT1.1 SOSIP trimer as a safe immunogen for elicitation of life-long HIV bnAb B cell lineages when administered in early life.
Role: Project 2 Lead
R01AI184074 - 09/2025-08/2029 - NIH/NIAID
Leveraging novel pediatric SHIVs to identify biomarkers of prophylactic efficacy of bnAb against breast milk HIV transmission
PI: Genevieve Fouda, MD, PhD, Weill Cornell Medicine
The overall goal of this project is to define a biomarker to predict the efficacy of combination bnAb passive immunization for the prevention of breast milk HIV transmission.
Role: PI
R21 HD118592-01 - 04/2025-03/2027 - NIH/NICHD
Defining and modeling HIV-1-specific antibody function in HIV-1-exposed Infants passively Infused with broadly neutralizing antibodies in the IMPAACT P1112 trial.
MPI: Genevieve Fouda, MD, PhD, Weill Cornell Medicine
The overall goal of this study is to determine if HIV-1 exposed infants passively immunized with CD4-bs bnAbs in the IMPAACT P1112 trial attained high serum neutralization titers against BM transmitted HIV viruses and if the level of serum neutralization can be predicted by a biomarker.
Role: MPI
UM1 AI164566 - 08/2021-04/2026- Johns Hopkins University via NIAID
Pediatric Adolescent Virus Eradiation (PAVE) Martin Delaney Collaboratory
MPI: Deborah Persaud, MD, Johns Hopkins
The overarching goal of this RF is to generate novel interventions for attaining ART-free control of pediatric HIV infection remission.
Role: Co-PI
R01 AI161008 - 09/2021-08/2026 - NIH/NIAID
Early life B cell responses and inflammation following SARS-CoV-2 infection
MPI: Genevieve Giny Fouda, MD, PhD (contact)
Major Goals: We propose to 1) characterize age-specific immune responses elicited by SARS-CoV-2; 2) define mechanisms driving protective immune responses; and 3) assess the relationship between virus- specific immune responses and symptomatic disease. We will use longitudinal samples from two unique previously enrolled household cohorts of SARS-CoV-2-infected children and adults.
Role: PI
R01 AI167850 - 04/2022-03/2027 – Duke University via NIAID
Impact of Early-life Exposure to Semi-Volatile Organic Compounds (SVOCs) on Neonatal and Early Childhood Immune Function
MPI: Kate Hoffman, PhD, Duke University
Major Goals: The overall goal of this study is to assess the development of HIV-specific antibody responses in young children.
Role: PI Subaward
R01 AI143370-04 - 03/2019-02/2025 NCE - NIH/NIAID
Neutralizing and non-neutralizing antibody effector functions in HIV infected children
MPI: Genevieve Giny Fouda
The overall goal of this study is to assess the development of HIV-specific antibody responses in young children.
Role: PI
R01 AI145016 - 04/2019-03/2025 NCE - Duke University via NIAID
Supramolecular pediatric HIV vaccine design
MPI: Joel Collier, Duke University
The goal of this project is to develop an innovative nanofiber pediatric HIV vaccine comprised of a scaffolded CH505 SOSIP Env trimer and a synthetic T-Cell epitope (PADRE) self-assembled into supramolecular nanofibers and to test if the PADRE- HIV-1 Env trimer vaccine enhances the magnitude and potency of tier 2 virus neutralization responses in small animal and infant primate models.
Role: PI, Subaward